Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice

Vaccine

Volumn 25, Issue 28, 2007, Pages 5166-5174

  Devi, Yengkhom Sangeeta ^a   Mukherjee, Paushali ^a   Yazdani, Syed Shams ^a   Shakri, Ahmad Rushdi ^a   Mazumdar, Suman ^a   Pandey, Sunita ^a   Chitnis, Chetan E ^a   Chauhan, Virander S ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY ICGEB   (India)

Author keywords

Humoral response; Malaria vaccine; Plasmodium vivax

Indexed keywords

ADJUVANT; ALUMINUM HYDROXIDE; DUFFY BINDING PROTEIN; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1; MONTANIDE ISA 720; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG MECHANISM; DRUG SYNTHESIS; HUMORAL IMMUNITY; IMMUNOGENICITY; MOUSE; NONHUMAN; PLASMODIUM VIVAX; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIBODY FORMATION; ANTIGENS, PROTOZOAN; BLOTTING, WESTERN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNIZATION; IMMUNOGLOBULIN G; MALARIA VACCINES; MALARIA, VIVAX; MALE; MEROZOITE SURFACE PROTEIN 1; MICE; MICE, INBRED BALB C; PLASMODIUM VIVAX; PROTOZOAN PROTEINS; RECEPTORS, CELL SURFACE; RECOMBINANT PROTEINS; TIME FACTORS;

EID: 34250213622     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.04.080     Document Type: Article

References (47)

1. Mendis K., Sena B.J., Marchesini P., and Carter R. The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg 64 Suppl. (2001) 97-106
2. Carter R., and Mendis K.N. Evolutionary and historical aspects of the burden of malaria. Clin Microbiol Rev 15 (2002) 564-594
3. Galinski M.R., and Barnwell J.W. Plasmodium vivax: merozoite, invasion of reticulocyes, and considerations for malaria vaccine development. Parasitol Today 12 (1996) 20-29
4. Bunnag D., Karbwang J., Thanavibul A., Chittamas S., Ratanapongse Y., and Chalemrut K. High dose of primaquine in primaquine resistant P. vivax malaria. Trans R Soc Trop Med Hyg 88 (1994) 218-219
5. Ratcliff A., Siswantoro H., Kenangalem E., Wuwung M., Brockman A., Edstein M., et al. Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. Trans R Soc Trop Med Hyg 101 (2007) 351-359
6. Schunk M., Kumma W., Miranda I., Osman M., Roewer S., Alano A., et al. High prevalence of drug-resistance mutations in Plasmodium falciparum and Plasmodium vivax in southern Ethiopia. Malar J. 5 (2006) 54
7. Arevalo-Herrera M., and Herrera S. Plasmodium vivax malaria vaccine development. Mol Immunol 38 (2001) 443-455
8. Galinski M.R., Corredor C., Ingravalio P., and Barnwell J.W. A reticulocyte-binding protein complex of Plasmodium vivax merozoite. Cell 69 (1992) 1213-1226
9. Rodriguez L.E., Urquiza M., Ocampo M., Curtidor H., Suarez J., Garcia J., et al. Plasmodium vivax MSP-1 peptides have high specific binding activity to human reticulocytes. Vaccine 20 January (2002) 1331-1339
10. Holder A.A., and Blackman M.J. What is the function of MSP-1 on the malaria merozoite?. Parasitol Today 10 (1994) 182-184
11. Blackman M.J., Heidrich H., Donachie S., McBride J.S., and Holder A.A. A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. J Exp Med 172 (1990) 379-382
12. Chitarra V., Holm I., Bentley G.A., Petres S., and Longacre S. The crystal structure of C-terminal merozoite surface protein 1 at 18 Å resolution, a highly protective malaria vaccine candidate. Mol Cell 3 (1999) 457-464
13. Del Portillo H.A., Longacre S., Khouri E., and David P.H. Primary structure of the merozoite surface antigen- 1 of Plasmodium vivax reveals sequences conserved between different Plasmodium spp. Proc Natl Acad Sci USA 88 (1991) 4030-4034
14. Ling I.T., Ogun S.A., and Holder A.A. The combined epidermal growth factor-like modules of P. yoelii merozoite surface protein-1 are required for a protective immune response to the parasite. Parasite Immunol 17 (1995) 425-433
15. Calvo P.A., Daly T.M., and Long C.A. Both epidermal growth factor-like domains of the merozoite surface protein-1 from P. yoelii are required for protection from malaria. Ann NY Acad Sci 797 (1996) 260-262
16. Holder A.A., and Freeman R.R. Immunization against blood-stage rodent malaria using purified parasite antigens. Nature 294 (1981) 361-364
17. Daly T.M., and Long C.A. Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria. J Immunol 155 (1995) 236-243
18. John C.C., O'Donnell R.A., Sumba P.O., Moormann A.M., de Koning-Ward T.F., King C.L., et al. Evidence that invasion-inhibitory antibodies specific for the 19-kDa fragment of merozoite surface protein-1 (MSP-1 19) can play a protective role against blood-stage Plasmodium falciparum infection in individuals in a malaria endemic area of Africa. J Immunol 173 (2004) 666-672
19. Kumar S., Collins W., Egan A., Yadava A., Garraud O., Blackman M.J., et al. Immunogenicity and efficacy in Aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1. Infect Immun 68 (2000) 2215-2223
20. Singh S., Miura K., Zhou H., Muratova O., Keegan B., Miles A., et al. Long Immunity to recombinant Plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. Infect Immun 74 (2006) 4573-4580
21. Dutta S., Ware L.A., Barbosa A., Ockenhouse C.F., and Lanar D.E. Purification, characterization, and immunogenicity of a disulfide cross-linked Plasmodium vivax vaccine candidate Antigen, merozoite surface protein 1, expressed in Escherichia coli. Infect Immun 69 (2001) 5464-5470
22. Perera K.L., Handunnetti S.M., Holm I., Longacre S., and Mendis K. Baculovirus merozoite surface protein 1 C-terminal recombinant antigens are highly protective in a natural primate model for human Plasmodium vivax malaria. Infect Immun 66 (1998) 1500-1506
23. Kumar S., Yadava A., Keister D.B., et al. Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. Mol Med 1 (1995) 325-332
24. Kumar S., Collins W., Egan A., et al. Immunogenicity and efficacy in Aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1. Infect Immun 68 (2000) 2215-2223
25. 19) of Plasmodium vivax in Saimiri Boliviensis monkeys. Am J Trop Med Hyg 60 3 (1999) 350-356
26. Sachdeva S., Ahmad G., Malhotra P., Mukherjee P., and Chauhan V.S. Comparison of immunogenicities of recombinant Plasmodium vivax merozoite surface protein 1 19- and 42-Kilodalton fragments expressed in Escherichia coli. Infect Immun 72 (2004) 5775-5782
27. Chappel J.A., and Holder A.A. Monoclonal antibodies that inhibit Plasmodium falciparum invasion in vitro recognize the first growth factor-like domain of merozoite surface protein-1. Mol Biochem Parasitol 60 (1993) 303-311
28. Miller L.H., Mason S.J., Clyde D.F., and McGinniss M.H. The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N Engl J Med 295 August (6) (1976) 302-304
29. Barnwell J.W., and Wertheimer S.P. Plasmodium vivax: merozoite antigens, the Duffy blood group, and erythrocyte invasion. Prog Clin Biol Res 313 (1989) 1-11
30. Fang X.D., Kaslow D.C., Adams J.H., and Miller L.H. Cloning of the Plasmodium vivax Duffy receptor. Mol Biochem Parasitol 44 (1991) 125-132
31. Chitnis C.E., and Miller L.H. Identification of the erythrocyte binding domains of Plasmodium vivax and Plasmodium knowlesi proteins involved in erythrocyte invasion. J Exp Med 180 (1994) 497-506
32. Horuk R., Chitnis C.E., Darbonne W.C., Colby T.J., Rybicki A., Hadley T.J., et al. A receptor for the malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor. Science 26 (1993) 1182-1184
33. Choe H., Moore M.J., Owens M., Wright P.L., Vasileva N., Li N., et al. Sulphated tyrosines mediate association of chemokines and Plasmodium vivax Duffy binding protein with the Duffy antigen/receptor for chemokines (DARC). Mol Microbiol 55 (2005) 1413-1421
34. Hans D., Pattnaik P., Bhattacharyya A., Shakri A.R., Yazdani S.S., Sharma M., et al. Mapping binding residues in the Plasmodium vivax domain that binds Duffy antigen during red cell invasion. Mol Microbiol 55 (2005) 1423-1434
35. Miller L.H., Mason S.J., Dvorak J.A., McGinniss M.H., and Rothman I.K. Erythrocyte receptors for (Plasmodium knowlesi) malaria: Duffy blood group determinants. Science 189 (1975) 561-563
36. Michon P., Fraser T., and Adams J.H. Naturally acquired and vaccine-elicited antibodies block erythrocyte cytoadherence of the Plasmodium vivax Duffy binding protein. Infect Immun 68 (2000) 3164-3171
37. Singh A.P., Puri K., and Chitnis C.E. Antibodies raised against receptor-binding domain of Plasmodium knowlesi Duffy binding protein inhibit erythrocyte invasion. Mol Biochem Parasitol 31 (2002) 72-81
38. Singh S., Pandey K., Chattopadhayay R., Yazdani S.S., Lynn A., and Bharadwaj A. Biochemical, biophysical and functional characterization of bacterially expressed and refolded receptor binding domain of Plasmodium vivax Duffy binding protein. J Biol Chem 276 (2001) 17111-17116
39. Yazdani S.S., Shakri A.R., Mukherjee P., Baniwal S.K., and Chitnis C.E. Evaluation of immune responses elicited in mice against a recombinant malaria vaccine based on Plasmodium vivax Duffy binding protein. Vaccine 22 (2004) 3727-3737
40. Yazdani S.S., Shakri A.R., and Chitnis C.E. A high cell density fermentation strategy to produce recombinant malarial antigen in E. coli. Biotechnol Lett 26 (2004) 1891-1895
41. Ellman G.L. Tissue sulfhydryl groups. Arch Biochem Biophys 82 (1959) 70-77
42. Burns Jr. J.M., Flaherty P.R., Romero M.M., and Weidanz W.P. Immunization against Plasmodium chabaudi malaria using combined formulations of apical membrane antigen-1 and merozoite surface protein-1. Vaccine 21 (2003) 1843-1852
43. Zhang D., and Pan W. Evaluation of three Pichia pastoris-expressed Plasmodium merozoite proteins as a combination vaccine against infection with blood-stage parsites. Infect Immun 73 (2005) 6530-6536
44. Duffy P.E., and Kaslow D.C. A novel Malaria Protein, Pfs28, and Pfs25 are generally linked and synergistic as falciparum malaria transmission-blocking vaccines. Infect Immun 65 (1997) 1109-1113
45. Holder A.A. Malaria vaccines. Proc Natl Acad Sci USA 96 (1999) 1167
46. Xainli J., Cole-Tobian J.L., Baisor M., Kastens W., Bockarie M., Yazdani S.S., et al. Epitope-specific humoral immunity to Plasmodium vivax Duffy binding protein. Infect Immun 71 (2003) 2508-2515
47. Arevalo-Herrera M., Castellanos A., Yazdani S.S., Shakri A.R., Chitnis C.E., Dominik R., et al. Immunogenicity and protective efficacy of recombinant vaccine based on the receptor-binding domain of the Plasmodium vivax Duffy binding protein in Aotus monkeys. Am J Trop Med Hyg 73 (2005) 25-31